LEADER 01589nam a2200361 i 4500 001 991001161939707536 005 20020507112105.0 008 011016s1973 fr ||| | eng 035 $ab10182354-39ule_inst 035 $aLE00643171$9ExL 040 $aDip.to Fisica$bita 084 $a53(082.2) 084 $a53.3.2 084 $a53.3.3 084 $a539.7'54 084 $aQC794.8 111 2 $aMoriond Workshop on the Pomeron$0463376 245 14$aThe Pomeron :$bproceedings of the 8th Rencontre de Moriond (Meribel-les-Allues, France, March 4-16, 1973), vol. 2 /$cedited by J. Tran Thanh Van ; sponsored by the Laboratoire de l'Accelerateur Lineaire, Laboratoire de Physique Theorique et Hautes Energies, Laboratoire de Physique Theorique et Particules Elementaires 260 $aMarseille :$bCNRS,$c1973 300 $a1 v. :$bill. ;$c23 cm. 490 0 $aMoriond Workshop ;$v8 (Pt. 2) 490 0 $aRencontres de Moriond ;$v8 (Pt. 2) 650 4$aParticles (Nuclear physics)$xCongresses 700 1 $aTran-Thanh-Van, Jean 710 2 $aEcole Normale Supérieure$c :$bLaboratoire de l'Accelerateur Lineaire 710 2 $aLaboratoire de Physique Theorique et Hautes Energies 710 2 $aLaboratoire de Physique Theorique et Particules Elementaires 907 $a.b10182354$b17-02-17$c27-06-02 912 $a991001161939707536 945 $aLE006 53(042+082.2) MOR$g1$i2006000034319$lle006$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i10223502$z27-06-02 996 $aPomeron$9190624 997 $aUNISALENTO 998 $ale006$b01-01-01$cm$da $e-$feng$gfr $h4$i1 LEADER 04028nam 22004453 450 001 9910813504403321 005 20230629231822.0 010 $a9789280533606$b(electronic bk.) 010 $z9789280533590 035 $a(MiAaPQ)EBC7113890 035 $a(Au-PeEL)EBL7113890 035 $a(CKB)25165210100041 035 $a(OCoLC)1348480949 035 $a(EXLCZ)9925165210100041 100 $a20221019d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCOVID-19-related vaccines and therapeutics $ePreliminary insights on related patenting activity during the pandemic 210 1$aGeneva :$cWorld Intellectual Property Organization,$d2022. 210 4$d©2022. 215 $a1 online resource (83 pages) 311 08$aPrint version: Staff, World Intellectual Property Organization COVID-19-related vaccines and therapeutics Geneva : World Intellectual Property Organization,c2022 9789280533590 327 $aIntro -- _Hlk93048502 -- Acknowledgements -- Key findings -- Introduction -- Background - biology of COVID-19 -- Overview of patenting activity related to COVID-19 -- Patent filings during 2020-2021 -- Filing and publication of COVID-19-related patent applications over time -- COVID-19-related vaccine and therapeutic patent applicant profiles -- Research collaboration and IP strategies related to technologies important to COVID-19 vaccines and therapeutics -- Disclosure of sequences within patent documents -- COVID-19 vaccines -- Background - vaccine platforms -- Conventional vaccine platforms -- Novel vaccine platforms -- Patent and vaccine distribution by vaccine platform and published applicant location -- Speed of vaccine development -- COVID-19 vaccine patent landscape -- Core vaccine technologies, collaboration and licensing -- Analysis of WHO data on COVID-19 vaccines -- Timelines on key technologies for COVID-19 vaccine development -- Technologies relevant to mRNA vaccine -- Timeline details for adenovirus vaccine development -- Timeline details for vaccine adjuvant development -- COVID-19 therapeutics -- Background -- Analysis of COVID-19 therapeutics-related patent applications by substances type -- Top locations of patent applicants for COVID-19 therapeutics and their filing strategies -- Highlights of patent filings related to COVID-19 therapeutic development -- Patent filings related to development of small-molecule drugs for COVID-19 -- Patent filings related to the development of biologics for COVID-19 -- Patents related to antibodies for COVID-19 treatment -- Peptide and protein therapies -- Nucleic-acid-based therapies -- Aptamer-mediated therapy -- Cell-based therapies -- Other biologic-based therapies -- Analysis of COVID-19 therapeutics in clinical trials. 327 $aAnalysis of COVID-19 therapeutics data in the Milken Institute and Regulatory Affairs Professionals Society (RAPS) tracker data -- Distribution of COVID-19 drug candidates across small molecules and biologics, repurposed drugs and de novo synthesized drugs -- Classification of COVID-19 drug candidates in clinical trials by molecular nature and function -- Feature summary of examples of anti-COVID-19 drug candidates in clinical trials -- Perspectives -- Annex -- Data sources and methods -- Tables of vaccine types and candidates currently in clinical trials -- Examples of partial, early disclosure observed at the Israeli, U.K. and Singapore patent offices -- Glossary -- References -- Further reading. 606 $aCOVID-19 (Disease) 606 $aPatents 606 $aPatents (International law) 615 0$aCOVID-19 (Disease). 615 0$aPatents. 615 0$aPatents (International law). 700 $aStaff$b World Intellectual Property Organization$01648146 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 912 $a9910813504403321 996 $aCOVID-19-related vaccines and therapeutics$94082899 997 $aUNINA